Abstract
Therapeutic drug monitoring (TDM) is central to optimize drug efficacy in children, because the pharmacokinetics and pharmacodynamics of most drugs differ greatly between children and adults. Many factors should be analyzed to implement TDM in the pediatric population, including a validated pharmacological parameter and an analytical method adapted to children as limited sampling volumes and high sensitivity are required. The use of population approaches, new analytical methods such as saliva and dried blood spots, and pharmacodynamic monitoring give attractive options to improve TDM, individualize therapy in order to optimize efficacy and reduce adverse drug reactions.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Adam BW, Alexander JR, Smith SJ, Chace DH, Loeber JG, Elvers LH, Hannon WH (2000) Recoveries of phenylalanine from two sets of dried blood spot reference materials: prediction from hematocrit, spot volume, and paper matrix. Clin Chem 46:126–128
Agunod M, Yamaguchi N, Lopez R, Luhby AL, Glass GB (1969) Correlative study of hydrochloric acid, pepsin, and intrinsic factor secretion in newborns and infants. Am J Dig Dis 14:400–414
Brodehl J (1994) Consensus statements on the optimal use of cyclosporine in pediatric patients. Transplant Proc 26:2759–2762
Brunet M, Crespo M, Millan O et al (2007) Pharmacokinetics and pharmacodynamics in renal transplant recipients under treatment with cyclosporine and myfortic. Transplant Proc 39:2160–2162
Carry MR, Ringel SP, Starcevich JM (1986) Distribution of capillaries in normal and diseased human skeletal muscle. Muscle Nerve 9:445–454
Cheung CY, van der Heijden J, Hoogtanders K, Christiaans M, Liu YL, Chan YH, Choi KS, van de Plas A, Shek CC, Chau KF, Li CS, van Hooff J, Stolk L (2008) Dried blood spot measurement: application in tacrolimus monitoring using limited sampling strategy and abbreviated AUC estimation. Transpl Int 21:140–145
Conroy S et al (2000) Survey of unlicensed and off label drug use in paediatric wards in European countries. European Network for Drug Investigation in Children. BMJ 320:79–82
Dasgupta A, Dean R, Saldana S, Konnaman G, McLawhon RW (1994) Absorption of therapeutic drugs by barrier gels in serum separator blood collection tubes. Am J Clin Pathol 101:456–461
de Hoog M, Mouton JW, van den Anker JN (2004) Vancomycin: pharmacokinetics and administration regimens in neonates. Clin Pharmacokinet 43:417–440
de Jonge H, Naesens M, Kuypers DR (2009) New insights into the pharmacokinetics and pharmacodynamics of the calcineurin inhibitors and mycophenolic acid: possible consequences for therapeutic drug monitoring in solid organ transplantation. Ther Drug Monit 31:416–435
del Mar Fernández De Gatta M, Santos-Buelga D, DomÃnguez-Gil A et al (2002) Immunosuppressive therapy for paediatric transplant patients: pharmacokinetic considerations. Clin Pharmacokinet 41:115–135
Drobitch RK, Svensson CK (1992) Therapeutic drug monitoring in saliva: an update. Clin Pharmacokinet 23:365–379
Edelbroek PM, van der Heijden J, Stolk LM (2009) Dried blood spot methods in therapeutic drug monitoring: methods, assays, and pitfalls. Ther Drug Monit 31:327–336
Fluhr JW, Pfisterer S, Gloor M (2000) Direct comparison of skin physiology in children and adults with bioengineering methods. Pediatr Dermatol 17:436–439
Fukudo M, Yano I, Masuda S et al (2005) Pharmacodynamic analysis of tacrolimus and cyclosporine in living-donor liver transplant patients. Clin Pharmacol Ther 78:168–181
Gorodischer R, Burtin P, Verjee Z, Hwang P, Koren G (1997) Is saliva suitable for therapeutic monitoring of anticonvulsants in children: an evaluation in the routine clinical setting. Ther Drug Monit 19:637–642
Greenblatt DJ, Koch-Weser J (1976) Intramuscular injection of drugs. N Engl J Med 295:542–546
Gross AS (2001) Best practice in therapeutic drug monitoring. Br J Clin Pharmacol 52(Suppl 1):5S–10S
Herkes GK, Eadie MJ (1990) Possible roles for frequent salivary antiepileptic drug monitoring in the management of epilepsy. Epilepsy Res 6:146–154
Hoogtanders K, van der Heijden J, Christiaans M, Edelbroek P, van Hooff JP, Stolk LM (2007) Therapeutic drug monitoring of tacrolimus with the dried blood spot method. J Pharm Biomed Anal 44:658–664
Ince I, de Wildt SN, Tibboel D, Danhof M, Knibbe CA (2009) Tailor-made drug treatment for children: creation of an infrastructure for data-sharing and population PK-PD modelling. Drug Discov Today 14:316–320
Irtan S, Azougagh S, Monchaud C, Popon M, Baudouin V, Jacqz-Aigrain E (2008) Comparison of high-performance liquid chromatography and enzyme-multiplied immunoassay technique to monitor mycophenolic acid in paediatric renal recipients. Pediatr Nephrol 23:1859–1865
Irtan S, Saint-Marcoux F, Rousseau A, Zhang D, Leroy V, Marquet P, Jacqz-Aigrain E (2007) Population pharmacokinetics and bayesian estimator of cyclosporine in pediatric renal transplant patients. Ther Drug Monit 29:96–102
Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE (2003) Developmental pharmacology–drug disposition, action, and therapy in infants and children. N Engl J Med 18(349):1157–1167
Koal T, Burhenne H, Römling R, Svoboda M, Resch K, Kaever V (2005) Quantification of antiretroviral drugs in dried blood spot samples by means of liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 19:2995–3001
Koren G (1997) Therapeutic drug monitoring principles in the neonate. National Academy of Clinical Biochemistry. Clin Chem 43:222–227
la Marca G, Malvagia S, Filippi L, Fiorini P, Innocenti M, Luceri F, Pieraccini G, Moneti G, Francese S, Dani FR, Guerrini R (2008) Rapid assay of topiramate in dried blood spots by a new liquid chromatography–tandem mass spectrometric method. J Pharm Biomed Anal 48:1392–1396
la Marca G, Malvagia S, Filippi L, Luceri F, Moneti G, Guerrini R (2009) A new rapid micromethod for the assay of phenobarbital from dried blood spots by LC-tandem mass spectrometry. Epilepsia 50:2658–2662
Li W, Tse FL (2010) Dried blood spot sampling in combination with LC-MS/MS for quantitative analysis of small molecules. Biomed Chromatogr 24:49–65
Liu H, Delgado MR (1999) Therapeutic drug concentration monitoring using saliva samples. Focus on anticonvulsants. Clin Pharmacokinet 36:453–470
Marquet P, Sauvage FL, Loustaud-Ratti V, Babany G, Rousseau A, Lachâtre G (2010) Stability of ribavirin concentrations depending on the type of blood collection tube and preanalytical conditions. Ther Drug Monit 32:237–241
Mei JV, Alexander JR, Adam BW, Hannon WH (2001) Use of filter paper for the collection and analysis of human whole blood specimens. J Nutr 131:1631S–1636S
Mullangi R, Agrawal S, Srinivas NR (2009) Measurement of xenobiotics in saliva: is saliva an attractive alternative matrix? Case studies and analytical perspectives. Biomed Chromatogr 23:3–25
Oellerich M, Barten MJ, Armstrong VW (2006) Biomarkers: the link between therapeutic drug monitoring and pharmacodynamics. Ther Drug Monit 28:35–38
Okah FA, Wickett RR, Pickens WL, Hoath SB (1995) Surface electrical capacitance as a noninvasive bedside measure of epidermal barrier maturation in the newborn infant. Pediatrics 96:688–692
Payen S, Zhang D, Maisin A, Popon M, Bensman A, Bouissou F, Loirat C, Gomeni R, Bressolle F, Jacqz-Aigrain E (2005) Population pharmacokinetics of mycophenolic acid in kidney transplant pediatric and adolescent patients. Ther Drug Monit 27:378–388
Peng B, Boddy AV, Cole M, Pearson AD, Chatelut E, Rubie H, Newell DR (1995) Comparison of methods for the estimation of carboplatin pharmacokinetics in paediatric cancer patients. Eur J Cancer 31A:1804–1810
Plard C, Bressolle F, Fakhoury M, Zhang D, Yacouben K, Rieutord A, Jacqz-Aigrain E (2007) A limited sampling strategy to estimate individual pharmacokinetic parameters of methotrexate in children with acute lymphoblastic leukemia. Cancer Chemother Pharmacol 60:609–620
Quattrocchi F, Karnes HT, Robinson JD, Hendeles L (1983) Effect of serum separator blood collection tubes on drug concentrations. Ther Drug Monit 5:359–362
Rodbro P, Krasilnikoff PA, Christiansen PM (1967) Parietal cell secretory function in early childhood. Scand J Gastroenterol 2:209–213
Rutter N (1987) Percutaneous drug absorption in the newborn: hazards and uses. Clin Perinatol 14:911–930
Sanquer S, Schwarzinger M, Maury S et al (2004) Calcineurin activity as a functional index of immunosuppression after allogeneic stem-cell transplantation. Transplantation 77:854–858
Scheyer RD, Cramer JA (1990) Pharmacokinetics of antiepileptic drugs. Semin Neurol 10:414–420
Schütz E, Svinarov D, Shipkova M, Niedmann PD, Armstrong VW, Wieland E, Oellerich M (1998) Cyclosporin whole blood immunoassays (AxSYM, CEDIA, and Emit): a critical overview of performance characteristics and comparison with HPLC. Clin Chem 44:2158–2164
Self TH, Heilker GM, Alloway RR, Kelso TM, Abou-Shala N (1993) Reassessing the therapeutic range for theophylline on laboratory report forms: the importance of 5–15 micrograms/ml. Pharmacotherapy 13:590–594
Sheiner LB, Beal SL (1981) Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 9:503–512
Sherwin CM, Svahn S, Van der Linden A, Broadbent RS, Medlicott NJ, Reith DM (2009) Individualised dosing of amikacin in neonates: a pharmacokinetic/pharmacodynamic analysis. Eur J Clin Pharmacol 65:705–713
Soldin OP, Soldin SJ (2002) Review: therapeutic drug monitoring in pediatrics. Ther Drug Monit 24:1–8
Sommerer C, Giese T, Meuer S, Zeier M (2009) Pharmacodynamic monitoring of calcineurin inhibitor therapy: is there a clinical benefit? Nephrol Dial Transplant 24:21–27
Steinberg C, Notterman DA (1994) Pharmacokinetics of cardiovascular drugs in children. Inotropes and vasopressors. Clin Pharmacokinet 27:345–367
‘t Jong GW et al (2000) Unapproved and off-label use of drugs in a children’s hospital. N Engl J Med 343:1125
‘t Jong GW et al (2002) Unlicensed and off-label drug use in a paediatric ward of a general hospital in the Netherlands. Eur J Clin Pharmacol 58:293–297
Takahashi H, Ishikawa S, Nomoto S, Nishigaki Y, Ando F, Kashima T, Kimura S, Kanamori M, Echizen H (2000) Developmental changes in pharmacokinetics and pharmacodynamics of warfarin enantiomers in Japanese children. Clin Pharmacol Ther 68:541–555
ter Heine R, Hillebrand MJ, Rosing H, van Gorp EC, Mulder JW, Beijnen JH, Huitema AD (2009a) Quantification of the HIV-integrase inhibitor raltegravir and detection of its main metabolite in human plasma, dried blood spots and peripheral blood mononuclear cell lysate by means of high-performance liquid chromatography tandem mass spectrometry. J Pharm Biomed Anal 49:451–458
ter Heine R, Rosing H, van Gorp EC, Mulder JW, Beijnen JH, Huitema AD (2009b) Quantification of etravirine (TMC125) in plasma, dried blood spots and peripheral blood mononuclear cell lysate by liquid chromatography tandem mass spectrometry. J Pharm Biomed Anal 49:393–400
ter Heine R, Rosing H, van Gorp EC, Mulder JW, van der Steeg WA, Beijnen JH, Huitema AD (2008) Quantification of protease inhibitors and nonnucleoside reverse transcriptase inhibitors in dried blood spots by liquid chromatography–triple quadrupole mass spectrometry. J Chromatogr B Anal Technol Biomed Life Sci 867:205–212
Tod MM, Padoin C, Petitjean O (2001) Individualising aminoglycoside dosage regimens after therapeutic drug monitoring: simple or complex pharmacokinetic methods? Clin Pharmacokinet 40:803–814
Touw DJ, Neef C, Thomson AH, Cost-effectiveness of Therapeutic Drug Monitoring Committee of the International Association for Therapeutic Drug Monitoring and Clinical Toxicology (2005) Cost-effectiveness of therapeutic drug monitoring: a systematic review. Ther Drug Monit 27:10–17
Touw DJ, Westerman EM, Sprij AJ (2009) Therapeutic drug monitoring of aminoglycosides in neonates. Clin Pharmacokinet 48:71–88
van der Heijden J, de Beer Y, Hoogtanders K, Christiaans M, de Jong GJ, Neef C, Stolk L (2009) Therapeutic drug monitoring of everolimus using the dried blood spot method in combination with liquid chromatography–mass spectrometry. J Pharm Biomed Anal 50:664–670
van Rossum HH, de Fijter JW, van Pelt J (2010) Pharmacodynamic monitoring of calcineurin inhibition therapy: principles, performance, and perspectives. Ther Drug Monit 32:3–10
Walson PD (1998) Therapeutic drug monitoring in special populations. Clin Chem 44:415–419
Warner A, Privitera M, Bates D (1998) Standards of laboratory practice: antiepileptic drug monitoring. National Academy of Clinical Biochemistry. Clin Chem 44:1085–1095
Wilhelm AJ, den Burger JC, Vos RM, Chahbouni A, Sinjewel A (2009) Analysis of cyclosporin A in dried blood spots using liquid chromatography tandem mass spectrometry. J Chromatogr B Anal Technol Biomed Life Sci 877:1595–1598
Zhao W, Elie V, Baudouin V, Bensman A, André JL, Brochard K, Broux F, Cailliez M, Loirat C, Jacqz-Aigrain E (2010) Population pharmacokinetics and Bayesian estimator of mycophenolic acid in children with idiopathic nephrotic syndrome. Br J Clin Pharmacol 69:358–366
Zhao W, Baudouin V, Zhang D, Deschênes G, Le Guellec C, Jacqz-Aigrain E (2009) Population pharmacokinetics of ganciclovir following administration of valganciclovir in paediatric renal transplant patients. Clin Pharmacokinet 48:321–328
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Zhao, W., Jacqz-Aigrain, E. (2011). Principles of Therapeutic Drug Monitoring. In: Seyberth, H., Rane, A., Schwab, M. (eds) Pediatric Clinical Pharmacology. Handbook of Experimental Pharmacology, vol 205. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-20195-0_3
Download citation
DOI: https://doi.org/10.1007/978-3-642-20195-0_3
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-20194-3
Online ISBN: 978-3-642-20195-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)